Cargando…

The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review

Background: One of the greatest challenges for medicine is to find a safe and effective treatment for immune-related diseases. However, due to the low efficacy of the treatment available and the occurrence of serious adverse effects, many groups are currently searching for alternatives to the tradit...

Descripción completa

Detalles Bibliográficos
Autores principales: Leyendecker Jr., Alessander, Pinheiro, Carla Cristina Gomes, Amano, Mariane Tami, Bueno, Daniela Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141714/
https://www.ncbi.nlm.nih.gov/pubmed/30254638
http://dx.doi.org/10.3389/fimmu.2018.02056
_version_ 1783355755464753152
author Leyendecker Jr., Alessander
Pinheiro, Carla Cristina Gomes
Amano, Mariane Tami
Bueno, Daniela Franco
author_facet Leyendecker Jr., Alessander
Pinheiro, Carla Cristina Gomes
Amano, Mariane Tami
Bueno, Daniela Franco
author_sort Leyendecker Jr., Alessander
collection PubMed
description Background: One of the greatest challenges for medicine is to find a safe and effective treatment for immune-related diseases. However, due to the low efficacy of the treatment available and the occurrence of serious adverse effects, many groups are currently searching for alternatives to the traditional therapy. In this regard, the use of human mesenchymal stem cells (hMSCs) represents a great promise for the treatment of a variety of immune-related diseases due to their potent immunomodulatory properties. The main objective of this study is, therefore, to present and summarize, through a systematic review of the literature, in vivo studies in which the efficacy of the administration of hMSCs for the treatment of immune-related diseases was evaluated. Methods: The article search was conducted in PubMed/MEDLINE, Scopus and Web of Science databases. Original research articles assessing the therapeutic potential of hMSCs administration for the in vivo treatment immune-related diseases, published from 1984 to December 2017, were selected and evaluated. Results: A total of 132 manuscripts formed the basis of this systematic review. Most of the studies analyzed reported positive results after hMSCs administration. Clinical effects commonly observed include an increase in the survival rates and a reduction in the severity and incidence of the immune-related diseases studied. In addition, hMSCs administration resulted in an inhibition in the proliferation and activation of CD19(+) B cells, CD4(+) Th1 and Th17 cells, CD8(+) T cells, NK cells, macrophages, monocytes, and neutrophils. The clonal expansion of both Bregs and Tregs cells, however, was stimulated. Administration of hMSCs also resulted in a reduction in the levels of pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-1, IL-2, IL-12, and IL-17 and in an increase in the levels of immunoregulatory cytokines such as IL-4, IL-10, and IL-13. Conclusions: The results obtained in this study open new avenues for the treatment of immune-related diseases through the administration of hMSCs and emphasize the importance of the conduction of further studies in this area.
format Online
Article
Text
id pubmed-6141714
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61417142018-09-25 The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review Leyendecker Jr., Alessander Pinheiro, Carla Cristina Gomes Amano, Mariane Tami Bueno, Daniela Franco Front Immunol Immunology Background: One of the greatest challenges for medicine is to find a safe and effective treatment for immune-related diseases. However, due to the low efficacy of the treatment available and the occurrence of serious adverse effects, many groups are currently searching for alternatives to the traditional therapy. In this regard, the use of human mesenchymal stem cells (hMSCs) represents a great promise for the treatment of a variety of immune-related diseases due to their potent immunomodulatory properties. The main objective of this study is, therefore, to present and summarize, through a systematic review of the literature, in vivo studies in which the efficacy of the administration of hMSCs for the treatment of immune-related diseases was evaluated. Methods: The article search was conducted in PubMed/MEDLINE, Scopus and Web of Science databases. Original research articles assessing the therapeutic potential of hMSCs administration for the in vivo treatment immune-related diseases, published from 1984 to December 2017, were selected and evaluated. Results: A total of 132 manuscripts formed the basis of this systematic review. Most of the studies analyzed reported positive results after hMSCs administration. Clinical effects commonly observed include an increase in the survival rates and a reduction in the severity and incidence of the immune-related diseases studied. In addition, hMSCs administration resulted in an inhibition in the proliferation and activation of CD19(+) B cells, CD4(+) Th1 and Th17 cells, CD8(+) T cells, NK cells, macrophages, monocytes, and neutrophils. The clonal expansion of both Bregs and Tregs cells, however, was stimulated. Administration of hMSCs also resulted in a reduction in the levels of pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-1, IL-2, IL-12, and IL-17 and in an increase in the levels of immunoregulatory cytokines such as IL-4, IL-10, and IL-13. Conclusions: The results obtained in this study open new avenues for the treatment of immune-related diseases through the administration of hMSCs and emphasize the importance of the conduction of further studies in this area. Frontiers Media S.A. 2018-09-11 /pmc/articles/PMC6141714/ /pubmed/30254638 http://dx.doi.org/10.3389/fimmu.2018.02056 Text en Copyright © 2018 Leyendecker, Pinheiro, Amano and Bueno. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Leyendecker Jr., Alessander
Pinheiro, Carla Cristina Gomes
Amano, Mariane Tami
Bueno, Daniela Franco
The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
title The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
title_full The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
title_fullStr The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
title_full_unstemmed The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
title_short The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
title_sort use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: a systematic review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141714/
https://www.ncbi.nlm.nih.gov/pubmed/30254638
http://dx.doi.org/10.3389/fimmu.2018.02056
work_keys_str_mv AT leyendeckerjralessander theuseofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview
AT pinheirocarlacristinagomes theuseofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview
AT amanomarianetami theuseofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview
AT buenodanielafranco theuseofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview
AT leyendeckerjralessander useofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview
AT pinheirocarlacristinagomes useofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview
AT amanomarianetami useofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview
AT buenodanielafranco useofhumanmesenchymalstemcellsastherapeuticagentsfortheinvivotreatmentofimmunerelateddiseasesasystematicreview